Current Edition

MCI Clinical Trials Within the New Alzheimer’s Criteria

Mild cognitive impairment (MCI) aims to identify cognitive decline in its earliest stages. Episodic memory impairment is typically a common cognitive marker in those with MCI who progress to AD-dementia, and each year around 10 to 115 per cent of individuals with amnestic MCI are diagnosed with AD-dementia. Teresa Leon of INC Research tells us that whilst nowadays there are no therapies that can prevent the conversation from MCI to AD-dementia, studies conducted with cholinesterase inhibitors have shown a modest cognitive improvement in MCI subjects (selected using the Petersen criteria) compared to placebo, but failed to prevent conversation from MCI to AD-dementia.